Why Are Lymph Nodes Removed? A Look at the Reasons

Lymph nodes are removed for three broad reasons: to find out whether cancer has spread beyond its original site, to treat cancer that has already reached the nodes, and to diagnose conditions like lymphoma that can only be confirmed by examining node tissue under a microscope. The relative weight of each reason depends on the type of cancer, its stage, and what your surgeon already knows going in. What has changed dramatically in recent decades is how many nodes get taken out, because surgeons now understand that removing more is not always better.

Staging a Cancer You Already Know About

When you are diagnosed with a solid tumor, one of the first things your oncology team wants to know is whether cancer cells have traveled beyond the primary site. Lymph nodes act as filters along the body’s lymphatic channels, so they tend to be the first place tumor cells land when they start to migrate. Examining those nodes under a microscope tells the pathologist whether metastasis has occurred, and that information directly shapes the treatment plan. A tumor that is confined to its organ of origin is staged and treated very differently from one that has seeded regional nodes.

The number of nodes examined matters for accuracy. In esophageal cancer, for example, international guidelines recommend removing at least six lymph nodes during surgery because removing fewer risks missing a positive node entirely, which would lead to an inaccurate staging classification.¹ In bladder cancer, the total number of nodes removed also influences how well staging systems predict survival in patients who turn out to be node-positive.² Understaging can mean a patient misses out on chemotherapy or radiation that could have made a real difference.

The Sentinel Node Idea

For much of the twentieth century, the standard approach was to remove entire chains of lymph nodes near a tumor. In breast cancer, that meant clearing the armpit of dozens of nodes. Surgeons eventually asked a sensible question: if cancer cells leave a tumor through lymphatic channels, would the very first node in the drainage path not be the most informative one to check? That node, called the sentinel lymph node, is now identifiable during surgery using a radioactive tracer, a blue dye, or both. The surgeon finds it, removes it, and sends it to the pathologist. If it is clean, the rest of the chain is typically left alone.³

This approach spares patients the complications of a full node dissection while still catching occult metastases in people who need further treatment.⁴ Sentinel node biopsy is now routine in breast cancer, melanoma, and several other solid tumors. It fundamentally changed the risk-benefit math: instead of removing thirty nodes to find the one that might be positive, you remove one or two nodes that are overwhelmingly likely to be the ones harboring cancer cells if any have escaped.

Treating Cancer That Has Already Reached the Nodes

Staging is about gathering information. Therapeutic lymph node dissection is about treatment. When imaging or a previous biopsy has already confirmed that cancer is sitting in regional lymph nodes, removing those nodes is a way to control the disease. In melanoma, patients with clinically evident lymph node metastases undergo therapeutic dissection to achieve regional control. The procedure carries considerable short-term complications, but it offers the potential for long-term cure in roughly one out of every four patients with stage III disease.⁵

Therapeutic dissections tend to be more extensive than sentinel biopsies and come with higher complication rates. The rationale is straightforward: cancer that is already living in the nodes can continue to grow there, seed more distant sites, and cause symptoms like pain or swelling. Removing the involved nodes eliminates a known reservoir of disease.

Elective Removal When Nodes Look Normal

Sometimes surgeons remove lymph nodes that appear clinically normal because statistical models suggest a high probability that microscopic cancer cells are already there. This is called elective lymph node dissection. In melanoma, the rationale rests on the idea that the disease spreads in an orderly fashion through lymph nodes before reaching distant organs, so catching micrometastases early could prevent later spread.⁶ Identifying patients with the right risk profile, high enough risk of hidden nodal disease but low enough risk of already having distant spread, is key to making elective dissection worthwhile.

In early-stage oral cancer where no suspicious nodes are detected on imaging, a meta-analysis of randomized trials found that elective neck dissection at the time of primary tumor removal reduced the chance of nodal recurrence and improved survival compared with a watch-and-wait strategy.⁷ The survival benefit tipped the scales in favor of upfront surgery even when the nodes looked clean on scans. For oral cancer in particular, this finding has shaped practice: many centers now recommend elective dissection as the default for tumors above a certain depth of invasion, rather than waiting for recurrence in the neck.

Diagnosing Lymphoma and Other Conditions

Not every lymph node removal is about a cancer you already know about. Sometimes a node becomes persistently enlarged and nobody is sure why. A needle biopsy can narrow the possibilities, but certain diagnoses, especially lymphoma, require the pathologist to see the full architecture of the node. You cannot accurately classify many lymphoma subtypes from a tiny needle sample because the patterns of abnormal cells matter as much as the cells themselves.

In one single-center analysis spanning twelve years of excisional lymph node biopsies, patients diagnosed with malignancy included cases of Hodgkin lymphoma, non-Hodgkin lymphoma with various subtypes, and metastatic cancers.⁸ A larger series evaluating 185 excisional biopsies found that about a third were benign, including reactive hyperplasia, cat-scratch disease, and granulomatous inflammation, while roughly two-thirds turned out to be malignant, dominated by non-Hodgkin lymphoma and Hodgkin lymphoma.⁹ The benign findings matter, too, because they give the patient an answer and prevent unnecessary chemotherapy. Excisional biopsy is considered the gold standard diagnostic method for persistent, unexplained lymph node enlargement.

What the Pathologist Does With the Nodes

Once a lymph node reaches the pathology lab, the analysis it undergoes depends on the clinical question. For sentinel nodes in breast cancer, protocols call for sectioning the node and staining it with standard dyes to look for clusters of tumor cells. Metastases larger than two millimeters (macrometastases) are the primary target because they reliably change clinical decisions about further treatment.¹⁰

More intensive examination, including staining deeper into the tissue block and using specialized immunohistochemical stains, can pick up smaller deposits called micrometastases and isolated tumor cell clusters. These smaller findings have some prognostic significance but do not reliably predict who will benefit from additional chemotherapy.¹⁰ The fact that sentinel node biopsy produces only a few nodes rather than dozens has allowed pathologists to examine each one far more closely than they could when dealing with a full axillary dissection, paradoxically improving detection of small deposits even as fewer nodes are sampled.¹¹

The Trend Toward Removing Fewer Nodes

Surgery on the lymphatic system has been moving steadily toward less aggressive approaches. In the late 1800s, the Halsted radical mastectomy involved removing the breast, both pectoral muscles, and all axillary lymph nodes.¹² By the 1980s, modified versions that preserved the chest muscles had become standard. Then breast-conserving surgery paired with sentinel node biopsy replaced even those.¹³ The arc of a century of breast cancer surgery is a steady retreat from removing everything in sight toward removing only what the evidence says you need.

That trend has continued into the present. In patients whose breast cancer has spread to one or two axillary nodes, trials have shown that skipping the full axillary dissection and relying on sentinel node biopsy alone does not lead to worse outcomes when combined with modern systemic therapy. For patients who receive chemotherapy before surgery (neoadjuvant chemotherapy) and achieve a complete pathologic response in the nodes, data now support omitting full axillary dissection entirely.¹⁴ Similarly, evidence from prospective trials has led to widespread abandonment of completion axillary dissection in patients whose sentinel nodes contain only micrometastases.¹⁵

This de-escalation is not about being lazy. It reflects accumulated evidence that full dissections often caused harm without improving survival, because the cancer cells in those extra nodes were already being handled by chemotherapy and radiation.

Lymphedema and Other Complications

The most feared long-term consequence of lymph node removal is lymphedema, a chronic swelling that develops when lymphatic fluid can no longer drain properly. The lymphatic system normally returns fluid, proteins, and immune cells from tissues back to the bloodstream. When surgery or radiation disrupts the lymphatic pathways, fluid accumulates in the affected limb or body region.¹⁶ The primary injury from surgery and radiation appears to be the root cause, though hemodynamic factors also contribute to chronic swelling.¹⁷

In the short term, the most common complication of axillary lymph node dissection is seroma, a pocket of fluid that collects under the skin at the surgical site. The reported incidence ranges widely, from about 3% to 85% depending on how it is defined and measured.¹⁸ Other short-term problems include wound infection, nerve injury, and reduced range of motion in the shoulder.

For head and neck dissections, the symptom profile looks different. Neck tightness was reported by about 71% of patients after surgery, numbness or burning of the ear by 57%, and shoulder discomfort by 53%. The encouraging news is that interference with daily life from these symptoms dropped significantly within two years of surgery. Quality of life after neck dissection was worse in patients who also had radiation or chemotherapy, or who had more extensive surgery, but it improved steadily over time.¹⁹

How Node Removal Affects Your Immune System

Lymph nodes are not just passive filters. They are active immune organs where immune cells encounter foreign material, activate, and multiply. Removing them is not immunologically neutral. A randomized trial in patients with early-stage lung cancer found that selective lymph node dissection caused less damage to cellular immune function than complete dissection, with patients recovering immune markers more quickly after the more limited operation.²⁰

The immune consequences are not just theoretical. Research using animal models has shown that the lymph nodes draining a tumor play a pivotal role in the response to immunotherapy drugs like PD-1/PD-L1 checkpoint inhibitors. Removing those specific tumor-draining nodes abolished the tumor regressions that immunotherapy would otherwise have produced.²¹ This finding has raised uncomfortable questions about whether aggressive lymph node dissection could undermine the effectiveness of immune-based treatments, which are increasingly central to cancer care.

A retrospective study of lung cancer patients suggested that limiting dissection to roughly 20 nodes may help preserve a favorable anti-tumor immune environment, compared with more extensive removal.²² These findings do not yet translate into firm clinical guidelines, but they add another dimension to the ongoing push for less aggressive lymph node surgery: preserving nodes may not just reduce complications, it may preserve the immune system’s ability to fight residual disease.

Preventing Lymphedema at the Time of Surgery

Given that lymphedema is the complication patients dread most, surgeons have developed techniques to reduce its likelihood during the very operation that causes it. One approach, known by the acronym LYMPHA, involves identifying lymphatic channels that are being severed during node dissection and immediately connecting them to small nearby veins. This creates an alternate drainage route before swelling ever has a chance to develop. Early results in the lower limb suggest the technique is feasible, safe, and effective at preventing lymphedema, with the added benefits of improved quality of life and lower long-term healthcare costs.²³

A related approach using lymphaticovenous bypasses performed at the time of axillary dissection for breast cancer has also shown promise, and the surgical teams performing these procedures have reported improving efficiency over time, making the additional operative steps more practical to incorporate into routine cancer surgery.²⁴ These preventive microsurgical techniques are not yet standard everywhere, but they represent a shift in thinking: rather than accepting lymphedema as an inevitable cost of lymph node surgery and treating it afterward, surgeons can now try to prevent it in the operating room.

When Fewer Nodes Means Better Outcomes

The quality-of-life data reinforce what the survival data already suggest. In a prospective study of women with early-stage breast cancer, those who had sentinel node biopsy alone experienced fewer complications than those who had full axillary dissection. Complications and systemic therapy both had significant effects on multiple dimensions of functioning, including role, emotional, cognitive, and social.²⁵ The women who developed complications reported meaningfully worse quality of life across multiple domains, a pattern that held regardless of whether they also received chemotherapy.

This finding underscores why the surgical community has been so eager to reduce the scope of lymph node surgery wherever the evidence supports it. Every node you leave in place is a piece of the lymphatic and immune system you have preserved. When trials show that leaving those nodes does not worsen cancer outcomes, the case for restraint becomes compelling. For patients heading into surgery, the practical question worth asking your surgeon is not just “how many nodes are you planning to remove?” but “what is the minimum number of nodes that will give us the staging information we need?”